share_log

SomaLogic (SLGC) Versus Its Rivals Head-To-Head Survey

SomaLogic (SLGC) Versus Its Rivals Head-To-Head Survey

SomaLogic(SLGC)与其竞争对手的正面调查
Defense World ·  2022/09/15 02:02

SomaLogic (NASDAQ:SLGC – Get Rating) is one of 41 publicly-traded companies in the "Commercial physical research" industry, but how does it contrast to its rivals? We will compare SomaLogic to related businesses based on the strength of its valuation, dividends, profitability, analyst recommendations, earnings, institutional ownership and risk.

纳斯达克(Sequoia Capital：SLGC-GET Rating)是商业物理研究领域的41家上市公司之一，但与竞争对手相比，它有什么不同？我们将根据SomaLogic的估值、股息、盈利能力、分析师建议、收益、机构所有权和风险等方面的实力，将SomaLogic与相关业务进行比较。

Profitability

盈利能力

This table compares SomaLogic and its rivals' net margins, return on equity and return on assets.

下表比较了SomaLogic及其竞争对手的净利润率、股本回报率和资产回报率。

Get
到达
SomaLogic
SomaLogic
alerts:
警报：
Net Margins Return on Equity Return on Assets
SomaLogic -114.46% -16.76% -14.61%
SomaLogic Competitors -239.39% -12.46% -6.20%
净利润率 股本回报率 资产回报率
SomaLogic -114.46% -16.76% -14.61%
SomaLogic竞争对手 -239.39% -12.46% -6.20%

Analyst Ratings

分析师评级

This is a summary of current ratings and recommmendations for SomaLogic and its rivals, as provided by MarketBeat.

这是对SomaLogic及其竞争对手的当前评级和推荐的摘要，由MarketBeat提供。

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SomaLogic 0 0 4 0 3.00
SomaLogic Competitors 42 618 1214 24 2.64
销售评级 保持评级 购买评级 强劲的买入评级 评级分数
SomaLogic 0 0 4 0 3.00
SomaLogic竞争对手 42 618 1214 24 2.64
SomaLogic currently has a consensus price target of $12.20, suggesting a potential upside of 222.75%. As a group, "Commercial physical research" companies have a potential upside of 45.16%. Given SomaLogic's stronger consensus rating and higher probable upside, analysts clearly believe SomaLogic is more favorable than its rivals.
SomaLogic目前的普遍目标价为12.20美元，这意味着潜在的上涨幅度为222.75%。作为一个整体，“商业物理研究”公司有45.16%的潜在上行空间。考虑到SomaLogic更高的共识评级和更高的可能上行空间，分析师们显然认为SomaLogic比其竞争对手更有利。

Risk and Volatility

风险和波动性

SomaLogic has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, SomaLogic's rivals have a beta of 5.23, suggesting that their average stock price is 423% more volatile than the S&P 500.

SomaLogic的贝塔系数为1.53，这表明其股价的波动性比标准普尔500指数高53%。相比之下，SomaLogic的竞争对手的贝塔系数为5.23，这表明它们的平均股价波动性比标准普尔500指数高423%。

Insider & Institutional Ownership

内部人与机构所有权

59.3% of SomaLogic shares are owned by institutional investors. Comparatively, 58.4% of shares of all "Commercial physical research" companies are owned by institutional investors. 12.9% of SomaLogic shares are owned by company insiders. Comparatively, 11.9% of shares of all "Commercial physical research" companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

SomaLogic 59.3%的股份由机构投资者持有。相比之下，所有“商业实体研究”公司58.4%的股份由机构投资者持有。SomaLogic 12.9%的股份由公司内部人士持有。相比之下，所有商业物理研究公司11.9%的股份由公司内部人士持有。强大的机构持股表明，捐赠基金、大型基金管理公司和对冲基金相信，一只股票有望实现长期增长。

Earnings and Valuation

收益和估值

This table compares SomaLogic and its rivals gross revenue, earnings per share and valuation.

此表比较了SomaLogic及其竞争对手的毛收入、每股收益和估值。

Gross Revenue Net Income Price/Earnings Ratio
SomaLogic $81.63 million -$87.55 million -4.55
SomaLogic Competitors $2.80 billion $97.54 million -16.77
总收入 净收入 市盈率
SomaLogic 8163万美元 -8,755万元 -4.55
SomaLogic竞争对手 28亿美元 9754万美元 -16.77

SomaLogic's rivals have higher revenue and earnings than SomaLogic. SomaLogic is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

SomaLogic的竞争对手比SomaLogic的收入和收益更高。SomaLogic的市盈率高于竞争对手，这表明它目前的价格高于同行业的其他公司。

Summary

摘要

SomaLogic beats its rivals on 7 of the 13 factors compared.

SomaLogic在比较的13个因素中有7个击败了竞争对手。

SomaLogic Company Profile

SomaLogic公司简介

(Get Rating)

(获取评级)

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

SomaLogic公司是美国的一家蛋白质生物标记物发现和临床诊断公司。它开发慢速修饰适体(SOMAmers)，这是一种针对其同源蛋白质的改良核酸蛋白质结合试剂；并提供专有的SomaScan服务，提供复杂生物样本中的多重蛋白质检测和蛋白质水平的量化。该公司的SOMAmers/SomaScan技术使研究人员能够分析各种类型的生物样本以寻找蛋白质生物标记物签名，这可用于药物发现和开发。其SomaScan的生物标志物发现有助于在各种疾病领域的诊断应用，包括心血管和代谢性疾病、非酒精性脂肪性肝炎、健康等。该公司还提供SomaSignal仅用于研究和实验室开发的测试。它以制药和生物技术公司以及学术研究机构为重点，为研究和临床客户提供服务，并通过评估蛋白质-蛋白质和蛋白质-基因网络，促进药物开发、临床试验分析和新的人类生物学见解。该公司成立于1999年，总部设在科罗拉多州博尔德市。

Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.

接受SomaLogic日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对SomaLogic和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发